Decipher Labs Share Price

Decipher Labs Limited is a pharmaceutical company engaged in the manufacture and marketing of pharmaceutical drugs and allied products. The company operates in the healthcare sector, supplying bulk drugs, chemicals, finished formulations, and allied products to customers in India. The Decipher Labs share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Decipher Labs stock price often mirrors shifts in pharmaceutical consumption patterns, demand for generic drugs, and investor views on the small-cap healthcare sector’s growth prospects. Factors such as the pace of product diversification, competitive intensity from larger pharmaceutical companies, raw material cost dynamics, and government policies on drug pricing influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Decipher Labs stock price movements.

Decipher Labs live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Decipher Labs live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Decipher Labs share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Decipher Labs Limited Company Fundamentals

a. Company Background

Decipher Labs Limited was incorporated in 1986. The company’s registered office is located in Hyderabad, Telangana. The company was initially incorporated as Combat Drugs Private Limited and was converted into a public limited company in June 1992. The name of the company was changed to Decipher Labs Limited in January 2020. The primary activity of the company involves the manufacture and trading of pharmaceutical drugs, including bulk drugs, chemicals, finished formulations, and allied products. The company offers a product mix including tablets, capsules, ointments, and liquids. Decipher Labs also provides custom manufacturing of non-sterile products and operates in two segments: Pharmaceuticals and IT Consultancy Services, with the pharmaceutical segment generating the maximum revenue. The company has faced significant regulatory challenges, including SEBI restrictions on capital market access and insider trading findings. Decipher Labs serves customers in India and has previously had an international presence in Bahrain, which was subsequently closed in 2025.

b. Product Lines

• Bulk drugs and finished pharmaceutical formulations

• Tablets, capsules, ointments and liquids for various therapeutic categories

• Products for recurring and chronic ailments including over-the-counter products

• Drugs for health, wellness and personal care

• Nutraceuticals, herbal and ayurvedic medications

• Lifestyle medications and other allied health products

• Information technology consultancy services

• Custom manufacturing of non-sterile pharmaceutical products

• Trading of pharmaceutical drugs and allied chemicals

• Bulk supply to development agencies and corporate customers

c. Company Revenue Model

• Primary revenue from manufacture and sale of pharmaceutical drugs

• Revenue from trading of bulk drugs and allied chemicals

• Pharmaceutical segment contributing maximum revenue among operating segments

• IT Consultancy Services revenue from technology solutions

• Bulk supply revenue through contracts with development agencies

• Custom manufacturing revenue for non-sterile pharmaceutical products

• Distribution-led revenue through pharmaceutical supply network

• Sourcing and supplying various drugs and allied products upon customer request

• Government and institutional contracts contributing to periodic revenue streams

• Commodity price cycles and raw material costs affecting overall revenue generation

d. Geographic Presence

• Operations primarily focused on the domestic Indian market

• Headquartered in Hyderabad, Telangana

• Previously had international presence with office in Bahrain which was approved for closure in August 2025

• Pharmaceutical products sold across India through distribution network

• IT consultancy services offered to domestic clients

• Geographic revenue primarily derived from India

• Subsidiary operations serving domestic pharmaceutical market

e. Key Milestones

• 1986: Incorporated as Combat Drugs Private Limited on September 17

• 1992: Converted into a Public Limited Company in June

• 2020: Name changed from Combat Drugs Limited to Decipher Labs Limited in January

• 2025: Board approved closure of Bahrain office due to geopolitical reasons in August

Decipher Labs Limited Industry Perspective

Decipher Labs operates in the Indian pharmaceutical industry, which is a significant component of the global healthcare sector. Globally, the pharmaceutical market was valued at approximately USD 1.6 trillion in 2024, with the Asia-Pacific region being the fastest-growing market. The global pharmaceutical market is projected to grow at a CAGR of 5.8 percent from 2025 to 2030, driven by ageing populations and increasing healthcare expenditure. In India, the pharmaceutical market was valued at USD 50 billion in 2024 and is projected to reach USD 130 billion by 2030, growing at a CAGR of 17 percent, according to IBEF. India is the largest provider of generic drugs globally, supplying over 50 percent of global demand for various vaccines and 40 percent of generic demand in the US. The domestic pharmaceutical market has recorded steady growth, with the government’s production-linked incentive scheme aiming to boost domestic manufacturing by Rs 1.5 lakh crore. The microcap pharmaceutical segment faces challenges including intense price competition, regulatory compliance costs, and raw material price volatility. Demand is driven by rising disease burden, increased health awareness post-pandemic, and government healthcare initiatives.

Decipher Labs Limited Stock Market Presence: Listings & Index Representation

Decipher Labs is actively traded on the Bombay Stock Exchange (BSE) with the scrip code 524752. The company is also listed on the National Stock Exchange of India (NSE) under the symbol DECIPHER. The ISIN number is INE643N01012. The company has a face value of Rs 10 per share. Being listed on both exchanges ensures that the Decipher Labs share price is accessible to a wide investor base, though the company’s microcap status limits institutional participation. The company forms part of the BSE Smallcap index and is classified under the Pharmaceuticals & Drugs industry. The inclusion of Decipher Labs in the BSE Smallcap index allows investors to benchmark the company’s stock performance relative to other small pharmaceutical companies, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The company is part of the ‘M’ group of securities on the BSE platform.

Decipher Labs Limited Stock Performance and Share Price History

The Decipher Labs share price has exhibited significant volatility over the past decade, shaped by the company’s regulatory challenges and microcap status in India’s pharmaceutical sector. The Decipher Labs share price recorded a negative total return of approximately -24.5 percent over the last 1 year and a negative return of -43.2 percent over the last 3 years, significantly underperforming broader market indices and reflecting near-term headwinds including SEBI restrictions and governance concerns. The Decipher Labs share price delivered a 5-year total return of -23.3 percent and a 10-year total return of -67.2 percent, demonstrating substantial long-term value erosion for shareholders. The Decipher Labs share price reached a 52-week high of 17.00 and a 52-week low of 5.33, indicating a wide trading range and substantial price fluctuations. The Decipher Labs share price has shown a 1-month return of approximately 11.6 percent and a 3-month return of -45.1 percent, indicating extreme volatility in the stock.

The Decipher Labs stock price has been particularly responsive to regulatory announcements and corporate actions regarding compliance issues. When the company faced SEBI restrictions on capital market access due to insider trading findings, the Decipher Labs stock price showed severe negative reactions. The Decipher Labs share price has shown a pattern of sharp declines followed by periodic rebounds in years when the company reported operational improvements, while periods of governance concerns have contributed to prolonged consolidation in the Decipher Labs stock price. Corporate developments, including the closure of the Bahrain office, have had limited positive influence on the Decipher Labs share price given the company’s overall fundamental challenges. The Decipher Labs share price has shown a 10-year aggregate net loss of approximately Rs 0.06 crore, reflecting the company’s inconsistent profitability over the long term. The Decipher Labs share price reached its 52-week high of 17.00 before declining to its 52-week low of 5.33, reflecting the volatility inherent in the microcap pharmaceutical space. The Decipher Labs share price has shown a year-to-date return of approximately -22.5 percent as of 2026, indicating continued pressure in the current fiscal year. Comprehending these patterns in the Decipher Labs share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics.

The Decipher Labs share price has shown limited seasonal patterns given its microcap status and regulatory challenges. The Decipher Labs price delivered best annual returns in years when the company reported operational improvements. The stock recorded negative annual returns across most of the past decade, with only intermittent positive years. The Decipher Labs price has demonstrated that the Decipher Labs stock price tends to perform poorly during periods of regulatory scrutiny and governance concerns, while showing occasional rebounds during phases of operational stabilization. The Decipher Labs price has shown a weekly volatility of 12 percent over the past year, which is higher than 75 percent of Indian stocks. The Decipher Labs share price has shown a current market capitalisation of approximately Rs 10 crore, reflecting the company’s microcap status. The Decipher Labs price continues to trade at a fraction of its historical highs, reflecting the significant challenges faced by the company in the competitive pharmaceutical market.

Decipher Labs Limited Investor Relevance and Role in Portfolio

Decipher Labs holds an insignificant position for portfolio investors due to its microcap status and significant governance concerns. The company’s presence in the pharmaceutical sector aligns it with investment strategies that value healthcare exposure, though institutional investors largely avoid the stock due to regulatory issues and lack of consistent profitability. The Decipher Labs price often reflects the broader challenges faced by small pharmaceutical companies with governance issues rather than industry fundamentals.

Institutional stakeholders play a negligible role in Decipher Labs ownership profile, with total promoters holding 16.43 percent of the company’s shares as of December 2025. Mutual fund holdings in Decipher Labs remain at 0 percent, with Domestic Institutional Investors holding 0 percent and Foreign Institutional Investors also holding 0 percent of the company. Retail investors account for 83.57 percent of public shareholding, reflecting the stock’s status as a highly retail-oriented speculative stock.

Based on data, the long-term beta of Decipher Labs is not reliably available due to inconsistent trading volumes. On a daily basis, the beta values vary significantly, with a one-month daily range and three-month daily range both showing high sensitivity in short-term trading. Moving to weekly observations, the weekly volatility of 12 percent has been stable over the past year but is still higher than 75 percent of Indian stocks. In contrast, the monthly two-year beta highlights higher responsiveness to broader market trends and speculative sentiment. Supporting statistics such as mean values and standard deviations further indicate extreme variability in performance across periods. The Decipher Labs price has shown periods of heightened responsiveness to quarterly earnings due to its microcap nature. The Decipher Labs stock price reflects that the company’s small size and limited liquidity may result in elevated volatility, though the pharmaceutical sector remains sensitive to regulatory compliance and raw material price fluctuations.

Decipher Labs Limited Sectoral Relevance and Peer Positioning

The sector relevance of Decipher Labs is anchored in its role within the broader Indian pharmaceutical microcap segment, where it competes with other small pharmaceutical manufacturers. As part of this industry, the company’s strategic positioning connects generic pharmaceutical products to institutional and retail customers. Competitors in the pharmaceutical microcap segment include companies such as Shamrock Industrial Company Limited, Colinz Laboratories Limited, Sanblue Corporation Limited, Vista Pharmaceuticals Limited, and Shree Ganesh Remedies Limited. Firms with parallels in either manufacturing scale or product portfolio are often referenced when evaluating relative performance within the sector.

In valuation terms, factors like the Decipher Labs P/E ratio have shown extreme variations over different periods, reflecting the company’s inconsistent profitability. The Decipher Labs P/E ratio has remained at 0.00 times in recent periods due to zero or negative earnings, with P/E staying in negative or zero territory across all recent fiscal years. The Decipher Labs P/E ratio has remained undefined in years when the company reported losses.

Similarly, the Decipher Labs EPS has shown minimal or zero values over the past decade. Decipher Labs earnings per share have remained at Rs 0.00 across most recent periods. Decipher Labs earnings for the full year recorded a net sales of Rs 22.61 crore in FY 2025, with the company operating at a net loss in some years and marginal profit in others. Decipher Labs market cap has fluctuated around Rs 7-10 crore range in line with investor perceptions of the company’s limited growth potential.

Over the years, the Decipher Labs market cap has remained extremely small, reflecting the company’s microcap status. The market cap has fluctuated between approximately Rs 7 crore and Rs 12 crore over the past several years. This limited size restricts institutional participation and the Decipher Labs price remains highly sensitive to small trading volumes.

Decipher Labs earnings over the past five years have been characterised by marginal profitability with significant losses interwoven. Net sales have fluctuated sharply, with total income recorded at Rs 87.60 lakhs in certain years with net losses. The company’s earnings volatility reflects its struggle to maintain consistent profitability in the competitive pharmaceutical industry. Operating revenue has shown sharp declines of nearly 89 percent year-on-year in some periods.

The Decipher Labs EPS has remained at Rs 0.00 or negligible across most of the past decade. Over the ten-year period since incorporation, the company has demonstrated inconsistent profitability, with earnings per share staying at zero or negative in most years. The Decipher Labs P/E ratio has remained at 0.00 over the ten-year period. The Decipher Labs share price continues to be evaluated in the context of its regulatory compliance and governance recovery. The Decipher Labs stock price remains highly speculative, reflecting market concerns about the company’s future prospects in the pharmaceutical industry.

Summary

Decipher Labs is a microcap pharmaceutical company listed on both the NSE and BSE, where the Decipher Labs share price reflects regulatory compliance issues, pharmaceutical industry cycles, and governance concerns within the healthcare sector. Its representation on stock indices supports basic market visibility, while investor interest is limited by earnings volatility and governance narratives. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s microcap pharmaceutical market.